Potential application of silver nanoparticles to control the infectivity of Rift Valley fever virus in vitro and in vivo

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 5, 2016, Pages 1185-1192

  Borrego, Belén ^a   Lorenzo, Gema ^a   Mota Morales, Josué D ^b   Almanza Reyes, Horacio ^c   Mateos, Francisco ^a   López Gil, Elena ^a   de la Losa, Nuria ^a   Burmistrov, Vasily A ^d   Pestryakov, Alexey N ^e   Brun, Alejandro ^a   Bogdanchikova, Nina ^b  

^a Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria Consejo Superior de Investigaciones Científicas   (Spain)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DE BAJA CALIFORNIA   (Mexico)

^d Scientific Production Centre Vektor Vita   (Russian Federation)

^e NATIONAL RESEARCH TOMSK POLYTECHNIC UNIVERSITY   (Russian Federation)

Author keywords

Antivirals; In vivo infection; Rift Valley fever virus; Silver nanoparticles

Indexed keywords

ANIMAL CELL CULTURE; CELL CULTURE; LANDFORMS; MAMMALS; METAL NANOPARTICLES; NANOPARTICLES; VIRUSES;

ANTIVIRAL ACTIVITIES; ANTIVIRALS; FEVER VIRUS; IN-VIVO; INFECTED CELLS; RIFT VALLEY FEVER VIRUS (RVFV); SILVER NANOPARTICLES; TYPE I INTERFERONS;

SILVER;

ANTIVIRUS AGENT; NEUTRALIZING ANTIBODY; SILVER NANOPARTICLE; NANOPARTICLE; SILVER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; ID50 (INFECTIOUS); IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; LETHAL DOSE; MOUSE; NONHUMAN; REPEATED DRUG DOSE; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; SINGLE DRUG DOSE; VERO CELL LINE; VIRUS LOAD; ANIMAL; DRUG EFFECTS; PATHOGENICITY;

ANIMALS; ANTIVIRAL AGENTS; MICE; NANOPARTICLES; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; SILVER;

EID: 84962330745     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2016.01.021     Document Type: Article

References (42)

1. Boshra H., Lorenzo G., Busquets N., Brun A. Rift Valley fever: recent insights into pathogenesis and prevention. J Virol 2011, 85:6098-6105.
2. Rolin A.I., Berrang-Ford L., Kulkarni M.A. The risk of Rift Valley fever virus introduction and establishment in the United States and European Union. Emerg Microbes Infect 2013, 2.
3. Kende M., Alving C.R., Rill W.L., Swartz G.M., Canonico P.G. Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice. Antimicrob Agents Chemother 1985, 27:903-907.
4. Scharton D., Bailey K.W., Vest Z., Westover J.B., Kumaki Y., Van Wettere A., et al. Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment. Antivir Res 2014, 104:84-92.
5. Peters C.J., Reynolds J.A., Slone T.W., Jones D.E., Stephen E.L. Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antivir Res 1986, 6:285-297.
6. Lorenzo G., Rodríguez-Pulido M., López-Gil E., Sobrino F., Borrego B., Sáiz M., et al. Protection against Rift Valley fever virus infection in mice upon administration of interferon-inducing RNA transcripts from the FMDV genome. Antivir Res 2014, 109:64-67.
7. Morrill J.C., Jennings G.B., Cosgriff T.M., Gibbs P.H., Peters C.J. Prevention of Rift Valley fever in Rhesus monkeys with interferon-α. Clin Infect Dis 1989, 11:S815-S825.
8. Rai M., Deshmukh S.D., Ingle A.P., Gupta I.R., Galdiero M., Galdiero S. Metal nanoparticles: the protective shield against virus infection. Crit Rev Microbiol 2014, 1-11.
9. Lv X., Wang P., Bai R., Cong Y., Suo S., Ren X., et al. Inhibitory effect of silver nanomaterials on transmissible virus-induced host cell infections. Biomaterials 2014, 35:4195-4203.
10. Khandelwal N., Kaur G., Chaubey K.K., Singh P., Sharma S., Tiwari A., et al. Silver nanoparticles impair Peste des petits ruminants virus replication. Virus Res 2014, 190:1-7.
11. Klippstein R., Fernandez-Montesinos R., Castillo P.M., Zaderenko A.P., Pozo D. Silver nanoparticles. InTech 2010, 309. D. Pozo (Ed.).
12. Podkopaev D.O., Shaburova L.N., Balandin G.V., Kraineva O.V., Labutina N.V., Suvorov O.A., et al. Comparative evaluation of antimicrobial activity of silver nanoparticles. Nanotechnol Russia 2014, 9:93-97.
13. Vazquez-Muñoz R., Avalos-Borja M., Castro-Longoria E. Ultrastructural analysis of Candida albicans when exposed to silver nanoparticles. PLoS One 2014, 9.
14. Semenov F.V., Fidarova K.M. The treatment of the patients presenting with chronic inflammation of the trepanation cavity with a preparation containing silver nanoparticles following sanitation surgery of the open type. Vestn Otorinolaringol 2012, 6:117-119.
15. Melnik E.A., Buzulukov Y.P., Demin V.F., Demin V.A., Gmoshinski I.V., Tyshko N.V., et al. Transfer of silver nanoparticles through the placenta and breast milk during in vivo experiments on rats. Acta Nat 2013, 5:107-115.
16. Demin V.A., Demin V.F., Buzulukov Y.P., Kashkarov P.K., Levin A.D. Formation of certified reference materials and standard measurement guides for development of traceable measurements of mass fractions and sizes of nanoparticles in different media and biological matrixes on the basis of gamma-ray and optical spectroscopy. Nanotechnol Russia 2013, 8:347-356.
17. Zaitseva N.V., Zemlyanova M.A., Zvezdin V.N., Dovbysh A.A., Akafyeva T.I., Gmoshinski I.V., et al. Experimental models and instrumental studies for the assessment of risk in the hygiene and epidemiology. Health Risk Anal 2015, 59-69.
18. Lorenzo G., Martín-Folgar R., Hevia E., Boshra H., Brun A. Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR(-/-) mice induced by different DNA vaccination regimens. Vaccine 2010, 28:2937-2944.
19. Speshock J., Murdock R., Braydich-Stolle L., Schrand A., Hussain S. Interaction of silver nanoparticles with Tacaribe virus. J Nanobiotechnol 2010, 8:19.
20. Xiang D., Zheng Y., Duan W., Li X., Yin J., Shigdar S., et al. Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo. Int J Nanomedicine 2013, 8:4103-4114.
21. Bouloy M., Janzen C., Vialat P., Khun H., Pavlovic J., Huerre M., et al. Genetic evidence for an interferon-antagonistic function of Rift Valley fever virus nonstructural protein NSs. J Virol 2001, 75:1371-1377.
22. Boshra H., Lorenzo G., Rodriguez F., Brun A. A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(-/-) mice upon lethal virus challenge. Vaccine 2011, 29:4469-4475.
23. Kalmantaeva O.V., Firstova V.V., Potapov V.D., Zyrina E.V., Gerasimov V.N., Ganina E.A., et al. Silver-nanoparticle exposure on immune system of mice depending on the route of administration. Nanotechnol Russia 2014, 9:571-576.
24. Galdiero S., Falanga A., Vitiello M., Cantisani M., Marra V., Galdiero M. Silver nanoparticles as potential antiviral agents. Molecules 2011, 16:8894-8918.
25. Bronze M.S., Huycke M.M., Machado L.J., Voskuhl G.W., Greenfield R.A. Viral agents as biological weapons and agents of bioterrorism. Am J Med Sci 2002, 323:316-325.
26. Borio L., Inglesby T., Peters C.J., et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. J Am Med Assoc 2002, 287:2391-2405.
27. Dos Santos C.A., Seckler M.M., Ingle A.P., Gupta I., Galdiero S., Galdiero M., et al. Silver nanoparticles: therapeutical uses, toxicity, and safety issues. J Pharm Sci 2014, 103:1931-1944.
28. Burmistrov V.A., Pestryakov A.N., Odegova G.V., Burmistrov I.V., Burmistrov A.V., Bogdanchikova N.E. Complex drug to prevent and treat intestinal infections. RU patent 2519659 2014.
29. Burmistrov V.A., Pestryakov A.N., Odegova G.V., Burmistrov I.V., Burmistrov A.V., Bogdanchikova N.E. Method of prevention and treatment of gastritis, stomach and duodenal ulcer. RU patent 2549975 2015.
30. Blagitko E.M., Rodionov P.P., Bugaichewnko N.V., Shorina G.N., Ilina V.N., Minina A.V., Mikhailov Y.I., Burmistrov V.A., Odegova G.V., Polunina O.A., Mikhailov Y.K., Bogdanchikova N.E., B.Avalos M., Antonov A.R., Rodionov A.P. Mean Argovit for treating the infected wounds. RU patent 2245151 2005.
31. Voronzova N.A., Rodionov P.P., Burmistrov V.A., Blagitko E.M., Mikhailov Y.I., Odegova G.V., Bogdanchikova N.E., B.Avalos M., Polunina O.A., Mikhailov K.Y., Dmitrieva L.A., Bernvald S.A. Method of treatment of ear, throat and nose diseases. RU patent 2307657 2007.
32. Gaikwad S., Ingle A., Gade A., Rai M., Falanga A., Incoronato N., et al. Antiviral activity of mycosynthesized silver nanoparticles against herpes simplex virus and human parainfluenza vitus type 3. Int J Nanomedicine 2013, 8:4303-4314.
33. Hu R.L., Li S.R., Kong F.J., Hou R.J., Guan X.L., Guo F. Inhibition effect of silver nanoparticles on herpes simplex virus 2. Genet Mol Res 2014, 3:7022-7028.
34. Trefry J.C., Wooley D.P. Silver nanoparticles inhibit vaccinia virus infection by preventing viral entry through a macropinocytosis-dependent mechanis. J Biomed Nanotechnol 2013, 9:1624-1635.
35. Soenen S.J., Parak W.J., Rejman J., Manshian B. (Intra)Cellular stability of inorganic nanoparticles: effects on cytotoxicity, particle functionality, and biomedical applications. Chem Rev 2015, 115:2109-2135.
36. Arvizo R.R., Bhattacharyya S., Kudgus R.A., Giri K., Bhattacharya R., Mukherjee P. Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chem Soc Rev 2012, 41:2943-2970.
37. Parveen S., Misra R., Sahoo S.K. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 2012, 8:147-166.
38. Trefry J.C., Wooley D.P. Rapid assessment of antiviral activity and cytotoxicity of silver nanoparticles using a novel application of the tetrazolium-based colorimetric assay. J Virol Methods 2012, 183:19-24.
39. Lara H.H., Ixtepan-Turrent L., Garza-Treviño E.N., Rodriguez-Padilla C. PVP-coated silver nanoparticles block the transmission of cell-free and cell-associated HIV-1 in human cervical culture. J Nanobiotechnol 2010, 8:15.
40. Lara H.H., Ayala-Nuñez N.V., Ixtepan-Turrent L., Rodriguez-Padilla C. Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnol 2010, 8:1.
41. Yu S.-j., Yin Y.-g., Liu J.-f. Silver nanoparticles in the environment. Environ Sci Process Impacts 2013, 15:78-92.
42. Elechiguerra J., Burt J., Morones J., Camacho-Bragado A., Gao X., Lara H., et al. Interaction of silver nanoparticles with HIV-1. J Nanobiotechnol 2005, 3:6.